CJC-1295 Biohacker and Longevity Stack Protocol: Doses, Timing, Labs, and Evidence

What Is CJC-1295 and Why Do Longevity Enthusiasts Use It?

CJC-1295 is a 30-amino-acid GHRH analogue engineered at ConjuChem Biotechnologies to resist proteolytic degradation. The drug-affinity complex (DAC) version covalently binds to serum albumin via a maleimidoproprionic acid linker, extending its half-life from minutes to nearly a week. The no-DAC version (sometimes called Modified GRF 1-29) has a 30-minute window, which maps better to physiological GH pulses.

Longevity practitioners use CJC-1295 because adult GH secretion declines approximately 14% per decade after age 30, a pattern well-documented in epidemiological surveys of the GH-IGF-1 axis. [1] Raising GH pulsatility through a secretagogue, rather than administering exogenous recombinant GH directly, is thought to preserve pituitary feedback loops and carry lower risk of excess GH-related side effects.

The GH-IGF-1 Axis in Brief

After CJC-1295 binds pituitary GHRH receptors, somatotroph cells release GH in pulses. The liver converts that GH into insulin-like growth factor-1 (IGF-1). IGF-1 is the downstream marker clinicians actually track. A 2006 Phase 1/2 randomized controlled trial (N=65) by Teichman et al. Published in the Journal of Clinical Endocrinology and Metabolism showed that a single 60 mcg/kg dose of CJC-1295 with DAC raised mean GH levels 2- to 10-fold and sustained elevated IGF-1 for up to 14 days. [2]

Why Secretagogues Over Exogenous GH?

Exogenous recombinant human GH (rhGH) suppresses endogenous GH production via negative feedback. CJC-1295 works upstream, amplifying the body's own pulsatile pattern. That distinction matters clinically: a 2019 Cochrane review of rhGH in adults with GH deficiency noted that supraphysiologic IGF-1 levels were associated with insulin resistance and fluid retention. [3] Staying within physiological IGF-1 ranges, which secretagogues may make easier, is a central argument in the longevity-stack rationale.

CJC-1295 Dosing Protocol for the Longevity Stack

Most published clinical data used weight-based dosing (mcg/kg), but practical longevity protocols use flat doses because peptide compounding is sold by vial concentration, not body weight.

CJC-1295 With DAC (Long-Acting)

• Starting dose: 1,000 mcg per week, split as 500 mcg twice weekly, subcutaneous
• Maintenance dose: 1,000 to 2,000 mcg per week once IGF-1 is confirmed in range
• Injection frequency: 2x per week (Monday/Thursday pattern is common)
• Timing: Morning, fasting, away from carbohydrate intake to avoid blunting GH release [4]

The Teichman 2006 RCT used doses of 30, 60, and 120 mcg/kg, which at an 80 kg reference body weight equals approximately 2,400, 4,800, and 9,600 mcg. Clinical longevity protocols stay substantially below those research doses, prioritizing sustained mild elevation over maximal acute response.

CJC-1295 Without DAC (Modified GRF 1-29)

• Dose per injection: 100 to 300 mcg subcutaneous
• Frequency: 1 to 3x daily, timed to natural GH pulse windows (see timing section below)
• When stacked with ipamorelin: Co-inject 100 to 200 mcg ipamorelin in the same syringe

The no-DAC form's short half-life means you must inject closer to the desired GH peak. Most practitioners prefer this version for the longevity stack because it mimics physiological pulsatility rather than creating a sustained tonic elevation.

Timing Relative to GH Pulses

Endogenous GH release peaks in three windows during a 24-hour cycle: within 60 to 90 minutes of sleep onset, mid-morning (approximately 1 hour post-waking), and around 2 hours after vigorous exercise. [5] Injecting CJC-1295 no-DAC 15 to 30 minutes before sleep is the most popular longevity approach. It amplifies the largest natural GH pulse and avoids food-related suppression of GH, because GH release is blunted by elevated free fatty acids and glucose.

Stacking CJC-1295: The Biohacker Protocol

CJC-1295 alone raises GH amplitude. Adding a ghrelin mimetic (GHRP class) raises GH pulse frequency. Together they produce a synergistic, supra-additive GH response. That phrase "synergistic" is used here in its strict pharmacological sense: the combination produces more GH than the additive sum of each compound alone, as shown in animal and early human secretagogue research. [6]

CJC-1295 Plus Ipamorelin

Ipamorelin is a selective GHRP that stimulates GH release without meaningfully raising cortisol or prolactin at standard doses, unlike first-generation GHRPs (GHRP-2, GHRP-6). A 1998 preclinical study in European Journal of Endocrinology established ipamorelin's selectivity profile. [7] The combination is the most common longevity-stack pairing.

Protocol:

• CJC-1295 no-DAC 200 mcg plus ipamorelin 200 mcg, co-injected subcutaneous, before sleep
• Optionally add a second injection 15 minutes before morning exercise
• Cycle: 12 weeks on, 4 to 6 weeks off

CJC-1295 Plus BPC-157

Some practitioners add BPC-157 (body protective compound-157) for tendon, gut, and connective tissue support. BPC-157 is a pentadecapeptide derived from human gastric juice protein. Its mechanism is distinct from GH secretagogues: it appears to upregulate growth factor receptor expression locally. [8] If stacking with BPC-157, inject BPC-157 separately (250 to 500 mcg subcutaneous or intramuscular near the target tissue), not in the same syringe as CJC-1295.

CJC-1295 Plus Sermorelin

Sermorelin is an older, shorter GHRH analogue (29 amino acids vs. 30 for CJC-1295). Some clinicians prefer it because it has a slightly longer prescribing history in the U.S. Pediatric GH deficiency context. Stacking CJC-1295 with sermorelin is generally not recommended: they compete for the same receptor and offer no additive benefit, while doubling cost and injection burden.

Cycle Length, On/Off Rationale, and Pituitary Reset

The rationale for cycling CJC-1295 is receptor downregulation. GHRH receptors on somatotrophs desensitize with sustained stimulation. The no-DAC form's short half-life already reduces this risk compared with DAC. For the DAC version, receptor downregulation is a real concern given sustained albumin-bound peptide levels.

Standard longevity cycle:

• On phase: 12 weeks
• Off phase: 4 to 8 weeks (longer for DAC; 4 weeks may suffice for no-DAC)
• Pituitary reset signal: IGF-1 returning to pre-cycle baseline within 4 weeks of stopping confirms the axis is responsive again

A 2004 study by Ionescu and Frohman in the Journal of Clinical Endocrinology and Metabolism documented that GHRH receptor mRNA expression in rat pituitary declined by approximately 40% after 14 days of continuous GHRH exposure, with recovery taking 7 to 14 days post-discontinuation. [9] While that is animal data, it informs the clinical rationale for off-cycles.

Expected Timeline of Outcomes

Realistic expectations prevent both early dropout and the chasing of supraphysiologic targets.

Weeks 1 to 4

• Sleep quality improvements reported anecdotally within 1 to 2 weeks (increased slow-wave sleep correlated with GH pulse amplitude)
• IGF-1 begins rising; first lab draw at week 4 to confirm response
• Some users report mild water retention and tingling extremities, which are GH-related effects and typically resolve by week 3

Weeks 4 to 8

• Lean body mass changes become measurable via DEXA or InBody scan (expect 0.5 to 2 kg increase at most over a full cycle in healthy adults)
• Fat mass changes are modest at physiological GH levels; a 2009 meta-analysis of GH treatment in healthy adults (N=220 across 31 RCTs) found mean fat mass reduction of 2.08 kg with rhGH but also noted that IGF-1 supraphysiologic elevation drove most of the adverse effects [10]
• Recovery from resistance training may subjectively improve

Weeks 8 to 12

• Body composition stabilization
• IGF-1 second lab draw at week 10 to 12 before stopping
• Assess subjective outcomes: sleep depth, energy, recovery

Monitoring Labs and Safety Thresholds

No large Phase 3 trials have established safety profiles for CJC-1295 in healthy aging adults. Evidence-grade for most lab thresholds is therefore "expert consensus / extrapolated from rhGH literature." Label it accordingly when you discuss this with a prescribing clinician.

Pre-Cycle Baseline Labs

| Lab | Why It Matters | |---|---| | IGF-1 (age/sex-adjusted) | Establish baseline; target upper third of reference range on-cycle | | Fasting glucose and HbA1c | GH is counter-regulatory to insulin; hyperglycemia is a key risk | | Fasting insulin and HOMA-IR | More sensitive early marker of insulin resistance than glucose alone | | Cortisol (AM, 8 AM draw) | CJC-1295 should not significantly raise cortisol; if it does, consider GHRP component | | Prolactin | Elevated prolactin can occur with some GHRPs; ipamorelin rarely causes this | | Thyroid panel (TSH, free T4) | GH affects thyroid hormone conversion; baseline useful | | Lipid panel | GH raises LDL transiently in some patients |

On-Cycle Lab Frequency

• Week 4: IGF-1, fasting glucose, fasting insulin
• Week 10 to 12: Full panel repeat before stopping
• 4 weeks post-cycle: IGF-1 only, to confirm axis recovery

IGF-1 Target Range

The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency defines normal adult IGF-1 as within 2 standard deviations of the age-sex mean. [11] Longevity practitioners typically aim for the 75th, 90th percentile of age-matched norms, not above the reference range. An IGF-1 above the upper limit of normal (ULN) for age is a signal to reduce dose or stop, given associations between chronically elevated IGF-1 and cancer risk seen in acromegaly literature. [12]

Glucose Monitoring

GH raises hepatic glucose output and induces peripheral insulin resistance. A 2007 review in Endocrine Reviews noted that rhGH increased fasting glucose by a mean of 0.3 mmol/L and insulin by approximately 20% in non-diabetic adults. [13] Anyone with pre-diabetes (HbA1c 5.7 to 6.4%) or a HOMA-IR above 2.5 should use CJC-1295 only under close clinical supervision with monthly glucose monitoring.

Injection Technique and Peptide Reconstitution

Proper reconstitution and storage determine peptide stability as much as the dosing protocol does.

Reconstitution Steps

1. CJC-1295 vials are typically lyophilized powder (5 mg or 2 mg per vial)
2. Add bacteriostatic water (not sterile water) using a 23-gauge needle; use 1 to 2 mL per 5 mg vial for easy volume dosing
3. Roll gently; never shake (shaking degrades peptide bonds)
4. Reconstituted peptide: refrigerate at 2 to 8°C, use within 28 to 30 days
5. Discard if cloudy or particulate matter appears

Injection Site and Technique

• Subcutaneous injection into periumbilical abdominal fat, alternating sides
• 29- or 31-gauge insulin syringe, 6 to 8 mm needle length
• Inject at a 45-degree angle; pinch skin fold if lean body type
• Rotate injection sites to prevent lipodystrophy

Regulatory Status, Compounding, and FDA Position

CJC-1295 is not FDA-approved for any indication. The FDA placed GHRH analogues including CJC-1295 on its list of bulk drug substances that may not be compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. [14] This means compounding pharmacies in the U.S. Are legally prohibited from making CJC-1295 for human use. Patients and practitioners should understand this regulatory reality before pursuing a protocol.

The FDA's 2023 guidance specifically named several peptides as "difficult to compound" or presenting "safety risks," and GHRH analogues were included in categories under active enforcement review. [14]

Sermorelin remains on the FDA-approved list for pediatric short stature (brand name Geref, though it is no longer commercially available from the innovator). Compounded sermorelin may be available through pharmacies operating under current FDA enforcement discretion, though this status can change. Tesamorelin (Egrifta SV) holds FDA approval for HIV-associated lipodystrophy and represents the only GHRH analogue with a current U.S. Indication. [15]

Evidence Grading Summary

Longevity influencers often present CJC-1295 protocols with a confidence level that outpaces the actual trial data. Here is an honest breakdown.

| Claimed Benefit | Best Available Evidence | Evidence Grade | |---|---|---| | Raises IGF-1 in healthy adults | Teichman 2006 RCT, N=65 [2] | Phase 1/2 RCT | | Improves body composition | Extrapolated from rhGH meta-analysis [10] | Indirect; no CJC-1295 specific data | | Improves sleep quality | Mechanistic data on GH pulse/slow-wave sleep [5] | Mechanistic; no RCT for CJC-1295 | | Anti-aging / longevity outcome | No trial data in healthy aging adults | Theoretical / anecdotal | | Ipamorelin combination selectivity | 1998 preclinical study [7] | Animal + Phase 1 data only |

The Endocrine Society's 2019 position statement on GH use in healthy older adults concluded: "We recommend against GH treatment for anti-aging or to improve body composition in otherwise healthy older adults due to insufficient evidence of benefit and the potential for harm." [16] That statement refers to exogenous rhGH, not secretagogues, but the evidence gap for secretagogues is even larger given fewer trials.

Who Should Not Use This Protocol

• Active malignancy or personal history of GH-sensitive tumors (breast, prostate, colon): IGF-1 may promote tumor proliferation [12]
• Pre-diabetes or type 2 diabetes without close monitoring: GH worsens insulin resistance
• Active acromegaly or pituitary adenoma: Stimulating GH further is contraindicated
• Pregnancy or breastfeeding: No safety data
• Age <25 years with open growth plates: GHRH stimulation in still-developing individuals carries unquantified risk
• Concurrent rhGH therapy: Redundant mechanism, supraphysiologic GH risk